Mahasti Saghatchian

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Hervé Bonnefoi, Thomas Grellety, Olivier Trédan et al. · Annals of Oncology · 2016 · 275 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +8

Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site

Stéphane Culine, Andrew Kramar, Mahasti Saghatchian et al. · Journal of Clinical Oncology · 2002 · 205 citations

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Eleftherios P. Mamounas, Michael Untch, Max S. Mano et al. · Annals of Oncology · 2021 · 119 citations · Full text

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Hervé Bonnefoi, William Jacot, Mahasti Saghatchian et al. · Annals of Oncology · 2014 · 86 citations · Full text

Breast Oncology, Medicine, Pathology +8

Chk1 as a new therapeutic target in triple-negative breast cancer

Laurence Albigès, Aïcha Goubar, Véronique Scott et al. · The Breast · 2014 · 61 citations · Full text